CD8A and neoplasm: A follow-up study found that a subgroup of patients with mCRPC with immune characteristics such as higher intratumor infiltrating CD8+ T cells, high IFN-γ response gene signals, and more robust antigen-specific T cell responses was more likely to achieve control of progression with ipilimumab monotherapy and more extended survival benefits, despite the relatively low tumor mutational load in this subset of patients (51).